Comparison of Plasminogen Activator Inhibitor-1, Tissue Type Plasminogen Activator Antigen, Fibrinogen, and D-Dimer Levels in Various Age Decades in Patients With Type 2 Diabetes Mellitus and Stable Coronary Artery Disease (from the BARI 2D Trial)

 Supported in part by grant R01 HL61744–BARI 2D parent grant from the National Institutes of Health, Bethesda, Maryland; grant U01HL63804–BARI II Fibrinolysis and Coagulation Core (B.E. Sobel, primary investigator) from the National Institutes of Health; and grant R01 HL71306–Inflammation, Procoagulation, and Plaque Vulnerability (B.E. Sobel, primary investigator) from the National Institutes of Health. The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trail was funded by grants U01 HL061744, U01 HL061746, U01 HL061748, and U01 HL063804 from the National Heart, Lung, and Blood Institute, Bethesda, Maryland, and the National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland. Significant supplemental funding has been provided by GlaxoSmithKline, Collegeville, Pennsylvania, Bristol-Myers Squibb Medical Imaging, Inc., North-Billerica, Massachusetts, Astellas Pharma US, Inc., Deerfield, Illinois, Merck & Co., Inc., Whitehouse Station, New Jersey, Abbott Laboratories, Inc., Abbott Park, Illinois, and Pfizer, Inc., New York, New York. Generous support was given by Abbott Laboratories, Inc., MediSense Products, Mississauga, Ontario, Canada, Bayer Diagnostics, Tarrytown, New York, Becton-Dickinson and Company, Franklin Lakes, New Jersey, JR Carlson Laboratories, Arlington Heights, Illinois, Centocor, Inc., Malvern, Pennsylvania, Eli Lilly and Company, Indianapolis, Indiana, LipoScience, Inc., Raleigh, North Carolina, Merck, Sante, Lyon, France, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, and Novo Nordisk, Inc., Princeton, New Jersey.

PII: S0002-9149(09)02208-5

doi: 10.1016/j.amjcard.2009.08.643

© 2010 Elsevier Inc. All rights reserved.